InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,001.35
(
0.10%
)
US TECH 100
20,544.80
(
-0.10%
)
Dow Jones
44,293.13
(
0.69%
)
Brent Oil
71.84
(
-2.53%
)
Bitcoin
87,654.19
(
8.91%
)
Post# of 253571
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

iwfal

Send PM Follow Ignore
Followers 75
Posts 4754
Boards Moderated 0
Alias Born 09/06/2003

iwfal

Member Level

Re: BTH post# 149904

Wednesday, 10/03/2012 12:31:17 AM

Wednesday, October 03, 2012 12:31:17 AM

Post# of 253571
ARQL -

"lets do a biomarker trial, sorta, but lets not truly drill down to the patients which will show the most success."



In fairness to ARQL the Met marker is probably a substantially stronger prognostic of treatment efficacy than most "Biomarker X"s are to "X inhibitor". And the move to such targeted therapies was just gathering steam when the ARQL ph ii finished.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up